United States
S. 1414
Expedited Access to Biosimilars Act
The bill would remove requirements for certain clinical studies on immunogenicity, pharmacodynamics, and comparative clinical effectiveness when manufacturers seek approval for biosimilar drugs—cheaper alternatives to existing biologic medications. This change aims to streamline and expedite the approval process for these follow-on biological products.[AI-Generated]
Reported by committee 27 July 2026
Record as of 27 July 2026 — the most recent action in the official record. Status can lag; each step below carries its own date.
- 27 July 2026 Reported by committee
What's next: Floor scheduling (leadership decides if and when it gets a vote)
- 27 July 2026 Placed on calendar (Senate)
1 more action
- 22 July 2026 Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
- 10 April 2025 Referred to committee
- 10 April 2025 Introduced in Senate
This path starts where the bill does — its first action in the official record. Routine procedural steps sit in the “more actions” rows above rather than on the main line.
Read the live feed — on the site or in the app Look up S. 1414 on Congress.gov All US bills